← Back to Search

Endurance Training for Physical Activity Benefits in Children (MoTrPAC Trial)

N/A

Recruiting

Led By Mike E Miller, PHS

Research Sponsored by University of Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Children and adolescents ages 10-17 (Pubertal stages 1-5)

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline; week 12

Awards & highlights

MoTrPAC Trial Summary

This trial is designed to study how physical activity affects molecular changes in children and adolescents.

Who is the study for?

This trial is for children and adolescents aged 10-17 who are in good health, weigh at least 30 kg, can speak English well enough to understand the study, and either engage in regular endurance sports or have limited intense exercise experience. They must not use tobacco or drugs, be pregnant, have donated blood recently, take chronic medication (except birth control), or have serious chronic diseases.Check my eligibility

What is being tested?

The MoTrPAC Pediatric Protocol examines how physical activity affects kids' bodies on a molecular level. It includes an acute exercise challenge to see immediate changes and a randomized controlled trial where participants do endurance training for about 12 weeks compared to a no-exercise group.See study design

What are the potential side effects?

Since this study involves standard physical activities like running or swimming as part of the endurance training intervention, potential side effects may include typical exercise-related discomforts such as muscle soreness, fatigue, and risk of injury.

MoTrPAC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 10 and 17 years old.

MoTrPAC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline; week 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline; week 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline; week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

CPET VO2 Peak

Isometric Knee Peak Torque by Group

Secondary outcome measures

HDL-C

HbA1C

LDL-C

+1 more

MoTrPAC Trial Design

4Treatment groups

Active Control

Group I: Cross Sectional LAActive Control1 Intervention

Do not participate in intervention after single acute exercise test of Endurance Exercise.

Group II: Cross Sectional HAActive Control1 Intervention

Do not participate in intervention after single acute exercise test of Endurance Exercise.

Group III: Endurance ExerciseActive Control1 Intervention

Participants randomized to EE participate in the intervention and complete the acute test and biospecimen collection following the intervention period.

Group IV: No Intervention ControlActive Control1 Intervention

The control group is randomized but does not participate in the intervention but does complete the acute test and biospecimen collection following the intervention period.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor

1,343 Previous Clinical Trials

716,106 Total Patients Enrolled

Icahn School of Medicine at Mount SinaiOTHER

865 Previous Clinical Trials

526,482 Total Patients Enrolled

Stanford UniversityOTHER

2,398 Previous Clinical Trials

17,342,055 Total Patients Enrolled

Media Library

Endurance Training Clinical Trial Eligibility Overview. Trial Name: NCT04151199 — N/A

Physical Activity Research Study Groups: Cross Sectional LA, Cross Sectional HA, Endurance Exercise, No Intervention Control

Physical Activity Clinical Trial 2023: Endurance Training Highlights & Side Effects. Trial Name: NCT04151199 — N/A

Endurance Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT04151199 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age restriction for this research study accommodate individuals younger than 35 years?

"To meet the study's entry requirements, participants must be between 10 and 17 years old."

Answered by AI

Are applicants being accepted for enrollment in this research study at present?

"Affirmative. According to information hosted on clinicaltrials.gov, this research initiative is actively seeking volunteers for participation. This trial was first uploaded November 22nd 2019 and the latest update occurred June 28th 2022; 320 candidates must be sourced from a single medical site."

Answered by AI

What are the qualifications necessary to participate in this investigation?

"This testing protocol is recruiting 320 minors aged between 10 and 17, with a Body Mass Index percentile of higher than 5th but lower than 95th, who weigh at least 30 kilograms for blood collection. Additionally, participants must be engaging in no more than two days per week of physical activity that last no longer than 120 minutes each time. Lastly, those involved should have been partaking regularly in intense endurance exercise (e.g., running, cycling etc.) for the past three months before enrolling as well as having taken part consistently four times or more every seven days over nine months prior to entry into the study."

Answered by AI

What is the extent of recruitment for this research endeavor?

"Affirmative. The information on clinicaltrials.gov demonstrates that this research is actively seeking participants, with the initial posting of November 22nd 2019 and last update occurring June 28th 2022. 320 patients are required to be recruited from 1 study site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Molecular Transducers of Physical Activity Consortium (MoTrPAC) - Pediatric Protocol

2019. "Molecular Transducers of Physical Activity Consortium (MoTrPAC) - Pediatric Protocol". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04151199.